Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joe Y Chang

Showing results (241-250 of 282) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
Frontiers in Oncology|November 5, 2021
Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal SubcommitteesMichael D Chuong, Christopher L Hallemeier, Heng Li, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2026
Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with RadiotherapyXinyan Xu, Maliazurina B Saad, Adam Grippin, et al.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
JAMA Oncology|September 19, 2019
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal CancerDawei Chen, Hari Menon, Vivek Verma, et al.
International Journal of Radiation Oncology, Biology, Physics|December 5, 2018
Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung CancerGregory M Videtic, Rebecca Paulus, Anurag K Singh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.
The Lancet. Respiratory Medicine|October 23, 2020
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trialsWillemijn S M E Theelen, Dawei Chen, Vivek Verma, et al.
Pageof 29

Showing results (241-250 of 282) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
Frontiers in Oncology|November 5, 2021
Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal SubcommitteesMichael D Chuong, Christopher L Hallemeier, Heng Li, et al.
Cancer Research|November 9, 2016
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by RadiotherapyXiaohong Wang, Jonathan E Schoenhals, Ailin Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2026
Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with RadiotherapyXinyan Xu, Maliazurina B Saad, Adam Grippin, et al.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
JAMA Oncology|September 19, 2019
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal CancerDawei Chen, Hari Menon, Vivek Verma, et al.
International Journal of Radiation Oncology, Biology, Physics|December 5, 2018
Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung CancerGregory M Videtic, Rebecca Paulus, Anurag K Singh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLCJames W Welsh, John V Heymach, Chunxiao Guo, et al.
The Lancet. Respiratory Medicine|October 23, 2020
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trialsWillemijn S M E Theelen, Dawei Chen, Vivek Verma, et al.
Pageof 29